Blog - Page 10 of 5508 - QualityStocks

TuesdayDec 02, 2025 9:45 am

OptimumBank Holdings Inc. (NYSE American: OPHC) Posts Higher Earnings, Loan Growth, and Expanding Deposits in Q3 2025

OptimumBank reported Q3 2025 net earnings of $4.32 million, an increase from both the prior quarter and the same period last year. Total deposits grew 9.17% from Q2 and nearly 19% year-over-year, reaching $959.49 million. Loans expanded during the quarter, driven by growth in commercial real estate and consumer lending. Net interest margin rose to 4.37%, supported by higher asset yields and improved funding costs. Leadership emphasized continued growth, strong capital levels, and a community-banking model centered on relationship banking. OptimumBank Holdings (NYSE American: OPHC), a bank holding company that owns 100% of community bank OptimumBank, headquartered in Fort Lauderdale,…

TuesdayDec 02, 2025 9:30 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) JV Sapu Nano Presents Data Showing Deciparticle Platform Supports Broad Hydrophobic Drug Formulation

Oncotelic Therapeutics (OTCQB: OTLC) said its 45%-owned joint venture, Sapu Nano, reported new data at the 2025 San Antonio Breast Cancer Symposium showing that its Deciparticle(TM) nanomedicine platform can consistently formulate structurally diverse hydrophobic therapeutics—including macrolide mTOR inhibitors, cyclic and linear peptides, ascomycin macrolactams and polyketides—into sub-20 nm nanoparticles suitable for IV delivery. The Company said the findings confirm Deciparticle as a versatile, cGMP-ready delivery platform backed by ISO-5 manufacturing capabilities that support rapid translation to Phase 1 supply. CEO Dr. Vuong Trieu said the results position Deciparticle as a modular engine for multiple oncology, immunology and peptide drug candidates,…

TuesdayDec 02, 2025 9:20 am

QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said the FDA has received its Abbreviated New Drug Application for KETAFREE(TM), a preservative-free intravenous ketamine formulation, deeming the submission “substantially complete” and assigning a July 29, 2026 review goal date. CEO Jonathan Javitt said KETAFREE is designed to provide a single-patient, preservative-free alternative to current multidose ketamine vials that contain Benzethonium Chloride, a compound no longer recognized as safe by the FDA. The Company said KETAFREE aligns with MAHA initiatives to remove toxic substances from medicines and supports domestic supply-chain priorities, with potential 2026 approved drug sales if approved on schedule.…

TuesdayDec 02, 2025 9:10 am

QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Schedules Corporate Update Call for Dec. 2

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it will host a corporate update conference call on Dec. 2, 2025, at 9 a.m. Eastern to review recent clinical, regulatory and operational developments. To view the full press release, visit https://ibn.fm/9WZCK About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal…

TuesdayDec 02, 2025 9:00 am

Nevada Organic Phosphate Inc. (CSE: NOP) Is ‘One to Watch’

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) and may include paid advertising. NOP is advancing what it believes to be the only known large-scale organic sedimentary phosphate project in North America. The company’s Murdock Mountain mineralization is uniquely pure, requiring no beneficiation and meeting the rare global threshold for direct-application P₂O₅. Exploration drilling in 2025 confirmed consistent Meade Peak phosphate-bearing stratigraphy across multiple holes exactly where geological models predicted. The project benefits from low-capex operational potential and immediate access to rail and road infrastructure near Montello, Nevada. With an ETMI range of 210–266 million tonnes across four…

MondayDec 01, 2025 3:30 pm

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Eyes 2026 Gold Production Launch in Renowned Abitibi Greenstone Belt

Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid advertising. Near term gold producer LaFleur Minerals is completing a Preliminary Economic Assessment (“PEA”) for the purpose of restarting production at its Beacon Gold Mill, sourcing from its Swanson Gold Project, both positioned in the renowned Abitibi Greenstone Belt of Quebec The company anticipates beginning to retrieve mineralized material from Swanson and processing it at Beacon in early 2026, benefitting from vast historical data from over 36,000 metres of drilling, including high-grade intervals that could be ideal for open pit mining scenario LaFleur Minerals combines near-term…

MondayDec 01, 2025 2:45 pm

GlobalTech Corp. (GLTK): Merging Telecom Infrastructure with Blockchain Innovation to Power Emerging Digital Economies

WorldCall’s fiber rollout ties into a broader tech transformation, with GLTK’s capital helping finance the network buildout that will serve as the foundation for future services such as AI, big data, and cloud Strategic partnership with World Mobile Chain positions GLTK to deploy enterprise-grade DePIN infrastructure across its telco asset base WMTx digital asset treasury initiative represents a novel approach to funding digital transformation while maintaining operational liquidity The Infrastructure Gap in Emerging Digital Economies Across South Asia, connectivity remains fragmented. While mobile penetration has surged, fixed broadband adoption lags, leaving millions without access to the high-speed infrastructure necessary for…

MondayDec 01, 2025 2:00 pm

SPARC AI Inc. (OTCQB: SPAIF) (CSE: SPAI) Differentiates from Drone Surveillance Competitors with GPS-Free, Software-First, and Continuous Intelligence

Disseminated on behalf of  SPARC AI Inc. (OTCQB: SPAIF) (CSE: SPAI) and may include paid advertising. SPARC AI Inc. offers autonomous navigation and target acquisition software for drones and other robotic systems The company’s technology differentiates from competitors by not relying on sensors, but having a software-first model, and offering continuous geospatial and behavioral intelligence At the heart of the company’s technology is Overwatch, an intelligence interface that combines targeting and navigation into a single capability SPARC AI (OTCQB: SPAIF) (CSE: SPAI), a drone technology and software developer, has created a target acquisition system and autonomous navigation software for drones…

MondayDec 01, 2025 1:53 pm

QualityStocksNewsBreaks – Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) CEO to Present at NobleCon21

Strawberry Fields REIT (NYSE AMERICAN: STRW) a self-administered REIT focused on healthcare-related properties, said Chairman and CEO Moishe Gubin will present at NobleCon21 on Dec. 3 at 4:30 p.m. Eastern at Florida Atlantic University’s Executive Education Complex. A high-definition webcast will be available on the NobleCon and Channelchek websites and will remain archived for 90 days. To view the full press release, visit https://ibn.fm/wOMyT About Strawberry Fields REIT Strawberry Fields REIT, Inc., is a self-administered real estate investment trust engaged in the ownership, acquisition, development and leasing of skilled nursing and certain other healthcare-related properties. The Company’s portfolio includes 142…

MondayDec 01, 2025 1:15 pm

Soligenix Inc. (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate

The enrollment milestone represents a crucial step forward for the FLASH2 study, which builds upon the previous statistically significant Phase 3 FLASH study. The promising early results are further corroborated by an ongoing investigator-initiated study being conducted at the University of Pennsylvania. Soligenix is positioning itself to potentially deliver the first FDA-approved photodynamic therapy specifically indicated for CTCL. In a pivotal advancement for patients suffering from a rare form of skin cancer, Soligenix (NASDAQ: SNGX) has achieved a critical clinical trial milestone that brings its investigational treatment significantly closer to potential FDA approval. The company announced that is has completed…

Site Search

Company Search